BusinessSummit Therapeutics Selected for Emerging Science Presentation at the 2018 American Academy of Neurology Annual MeetingBy Nasdaq OMXMar 28, 2018, 11:00 AM UTC
BusinessEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Aaron’s, Inc. – AANBy Nasdaq OMXJul 29, 2017, 1:20 AM UTC
BusinessMDA, AAN and ABF Award Clinical Research Training Fellowship for Muscular DystrophyBy Nasdaq OMXJul 14, 2017, 3:05 PM UTC
BusinessAdamas Presents ADS-5102 Pooled Phase 3 Data Confirming Statistically Significant Reduction in Levodopa-Induced Dyskinesia and OFF Time in People with Parkinson’s DiseaseBy Nasdaq OMXApr 24, 2017, 1:06 PM UTC
BusinessaTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual MeetingBy Nasdaq OMXApr 24, 2017, 12:02 PM UTC
BusinessaTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual MeetingBy Nasdaq OMXApr 24, 2017, 12:02 PM UTC
BusinessaTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual MeetingBy Nasdaq OMXApr 24, 2017, 12:02 PM UTC
BusinessaTyr Pharma Announces Promising Top-Line Results from Resolaris™ Phase 1b/2 Clinical Trial in Patients with Early Onset Facioscapulohumeral Muscular DystrophyBy Nasdaq OMXApr 24, 2017, 11:30 AM UTC
